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Drug-induced proarrhythmia constitutes a potentially lethal side effect of various drugs.
Most often, this proarrhythmia is mechanistically linked to the drug's potential to interact
with repolarizing cardiac ion channels causing a prolongation of the QT interval in the ECG.
Despite sophisticated screening approaches during drug development, reliable prediction
of proarrhythmia remains very challenging. Although drug-induced long-QT-related
proarrhythmia is often favored by conditions or diseases that impair the individual's
repolarization reserve, most cellular, tissue, and whole animal model systems used for
drug safety screening are based on normal, healthy models. In recent years, several
transgenic rabbit models for different types of long QT syndromes (LQTS) with differences
in the extent of impairment in repolarization reserve have been generated. These might be
useful for screening/prediction of a drug's potential for long-QT-related proarrhythmia,
particularly as different repolarizing cardiac ion channels are impaired in the different
models. In this review, we summarize the electrophysiological characteristics of the
available transgenic LQTS rabbit models, and the pharmacological proof-of-principle
studies that have been performed with these models—highlighting the advantages and
disadvantages of LQTS models for proarrhythmia research. In the end, we give an outlook
on potential future directions and novel models.
Keywords: transgenic LQTS rabbit, drug-induced proarrhythmia, proarrhythmia safety screening, K+-channel
blocker, long QT syndrome, cardiac repolarization reserveINTRODUCTION: PROARRHYTHMIA AND DRUG DEVELOPMENT
Proarrhythmia—the triggering of arrhythmias following drug therapy—has been known for many
decades as being caused by “anti”-arrhythmic cardiac drugs (Selzer and Wray, 1964; Echt et al.,
1991; Waldo et al., 1996). This rare but lethal side-effect of drug therapy, however, is not restricted to
anti-arrhythmic drugs, but occurs with a variety of other, non-cardiac drugs (Woosley et al., 1993;
Wysowski and Bacsanyi, 1996; Darpo, 2001), and therefore is a major concern for patients,
physicians, and the pharmaceutical industry. It has been estimated that around 20–60% of novel
chemical entities have the potential to modulate the function of cardiac ion channels and therefore,in.org June 2020 | Volume 11 | Article 8531
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2014). Depending on the nature of the drug-induced effects on
ion channels function, proarrhythmia can be associated with
prolongation or shortening of the QT interval (long QT
syndrome, LQTS or short QT syndrome, SQTS, respectively)
and/or with conduction disturbances.
For most drugs, proarrhythmia is assumed to be based on
prolongation of cardiac repolarization as a result of drug-
induced inhibition of cardiac potassium currents (mostly IKr
current(s)/HERG-channels) (Redfern et al., 2003). This acquired
LQTS predisposes to Torsades-de-Pointes (TdP) polymorphic
ventricular tachycardia that could lead to ventricular fibrillation
and sudden cardiac death (SCD) (Haverkamp et al., 2000;
Redfern et al., 2003; Fenichel et al., 2004). Although no less
than 2–3% of all marketed drugs have the potential to induce
LQTS (Stansfeld et al., 2006), the (documented) incidence of
potentially lethal drug-induced TdP is typically very low
(1:10,000 for non-cardiovascular drugs) (Yap and Camm,
2003), and therefore very hard to predict reliably (Fenichel
et al., 2004). In recent decades, TdP-induced SCD cases were
associated with a wide range of commonly used drugs (anti-
psychotics, anti-depressants, antihistamines, and antibiotics)
(Haverkamp et al., 2000; Redfern et al., 2003; Fenichel et al.,
2004) and many of them (such as cisapride, astemizole,
terfenadine, grepafloxacin) have been withdrawn from the
market (Farkas and Nattel, 2010; Stockbridge et al., 2013;
Ferdinandy et al., 2019).
As a response from the regulatory authorities, the
International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH)
guidelines [ICH-S7B, 2005 (Food and Drug Administration,
2005b); ICH-E14, 2005 (Food and Drug Administration,
2005a)] were proposed for rigorous safety testing to avoid
similar unacceptable human fatalities (SCD) in association
with pharmacological therapy of non-life-threatening
pathologies. Unfortunately, no “gold”-standard proarrhythmia
screening method exist. Therefore, current safety screening in
industry rely on combined use of pre-clinical in vitro assessment
of HERG function, action potential (AP) and in vivo ECG (QT)
assays, in silico computational (Yang et al., 2016; Ortega et al.,
2017; Li et al., 2019) risk prediction [integrated risk assessment
(IRA) approach], and clinical ECG studies (Food and Drug
Administration, 2005a; Food and Drug Administration,
2005b). Usually, different proarrhythmia markers and score
systems [see Proarrhythmia ECG Markers for Temporal
Instability of Repolarization (Used in In Vivo and In Vitro
Models)] are employed to try to increase the predictive value of
the overall assessment (Hondeghem et al., 2001; Hondeghem and
Hoffmann, 2003; Redfern et al., 2003; Lawrence et al., 2005) with
moderate to limited success (Park et al., 2018).
Drug-induced IKr/HERG blockade used to be considered the
most important factor responsible for proarrhythmia formation.
Therefore, for a long time, safety tests largely focused on detection
of HERG-blocking potential of test compounds. As a result, this
approach led to elimination of potentially promising drug
candidates from the developmental pipeline solely on the basisFrontiers in Pharmacology | www.frontiersin.org 2of their potential to block the HERG channel (Carlsson, 2001;
Bouder, 2007; Pugsley et al., 2008). HERG blockade plays an
inevitably important role in proarrhythmia formation (Yap and
Camm, 2003; Hancox et al., 2008); though, HERG block on its
own does not necessarily lead to proarrhythmia since
simultaneous reduction in other ion currents—such as in INa or
ICa—that may have anti-arrhythmic effects could modify the
overall proarrhythmic potential of the drug (Van Opstal et al.,
2001; Belardinelli et al., 2003; Thomsen et al., 2004; Anderson,
2006). On the other hand, compounds without HERG-blocking
characteristics may still have proarrhythmic side effect via the
inhibition of repolarizing ion currents such as the slow delayed
rectifier potassium current IKs or the inward rectifier potassium
current IK1 (Pugsley et al., 2008; Roden, 2008; Kannankeril et al.,
2010; Pollard et al., 2010). Based on the above, pharmaceutical
industry has started the Comprehensive in vitro Proarrhythmia
Assay (CiPA) initiative to work with validated assays, and to fill
gaps in the internal proarrhythmia assessment with the overall
goal to comply with the ICH-S7B guidelines. This new approach
consists of three main elements: 1) systematic measurement of the
effect of drug candidates on multiple human cardiac ion currents
(IKr, IKs, INa,peak, INa,late, IK1, Ito, ICa,L) in heterologous expression
systems (Kramer et al., 2013; Cavero and Holzgrefe, 2014;
Colatsky et al., 2016), 2) in silico integration of these ion
channel effects, and 3) evaluation of the drug effect on
integrated biological systems such as on stem-cell-derived
cardiomyocytes (Colatsky et al., 2016; Crumb et al., 2016;
Huang et al., 2017). According to a recent survey on current
industrial safety screening practice (Authier et al., 2017), 90% of
the pharmaceutical companies use cell lines expressing cardiac ion
channels, 50–60% of them perform ion channel binding assays,
cardiac AP recordings or use human induced pluripotent stem
cell-derived cardiomyocytes, and only around one-third of them
integrate their electrophysiological results into an in silico model
in order to better predict the drug effect on AP shape and
duration. The CiPA initiative is undoubtedly a promising
approach; however, its overall implementation is not sufficient yet.
The other major challenge in proarrhythmia screening
derives from the huge inter-individual differences in
susceptibility to arrhythmia, which makes the overall risk
stratification particularly difficult. Gender, sex hormones, K+
homeostasis, and—most importantly—certain diseases highly
influence the cardiac “repolarization reserve”, defined as the
ability of cardiomyocytes to maintain sufficient repolarization
despite repolarization-prolonging (mostly K+ channel blocking)
effects via compensatory increase of non-affected “reserve”
outward K+ currents (Roden, 1998; Varro and Baczko, 2011).
Apart from a decrease in serum K+ concentration that results
in a massive prolongation of cardiac repolarization, cardiovascular
and metabolic diseases such as congestive heart failure (Kjekshus,
1990), cardiac hypertrophy, hypertrophic and dilated
cardiomyopathy (Decker et al., 2009), ischemia (Dutta et al.,
2016), congenital LQTS (El-Sherif and Turitto, 1999), or
diabetes mellitus (Mcnally et al., 1999; Whitsel et al., 2005) play
the most important role in decreasing repolarization reserve
capacity and thereby in increasing susceptibility to proarrhythmia.June 2020 | Volume 11 | Article 853
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patients with reduced cardiac repolarization reserve, current
safety assessments rely still mainly on tests performed on
healthy animals with intact repolarization or on their tissues/
cells (Food and Drug Administration, 2005a; Food and Drug
Administration, 2005b). Consequently, new animal models, (i)
with increased sensitivity to channel blockers other than only
HERG, such as IKs or IK1, and (ii) representing different degrees
of impairment in their cardiac repolarization reserve were
suggested to employ in proarrhythmia research (Hornyik
et al., 2020).
Sex hormones also can significantly alter the individual's
repolarization reserve capacity and therefore affect susceptibility to
arrhythmia. Women are at higher risk for drug-induced
prolongation of repolarization and drug-induced TdP (Lehmann
et al., 1996; Benton et al., 2000;Wolbrette, 2003; Gowda et al., 2004).
This is due to sex hormone effects on cardiac ion currents/channels
(Yang and Clancy, 2010; Odening and Koren, 2014): estrogen
prolongs cardiac repolarization by decreasing IKs (Drici et al.,
1996) and IKr (Kurokawa et al., 2008; Ando et al., 2011) and by
increasing ICa,L (Odening et al., 2012a; Odening et al., 2012b) and
NCX expression (Chen et al., 2011); therefore, estrogen reduces
repolarization reserve and favors drug-induced arrhythmia. In
contrast, testosterone and progesterone both increase
repolarization reserve by increasing IKs [testosterone (Liu et al.,
2003)/progesterone (Furukawa and Kurokawa, 2008)], IK1 and IKr
(testosterone) (Liu et al., 2003), decreasing ICa,L [testosterone
(Furukawa and Kurokawa, 2008)/progesterone (Odening et al.,
2012a; Odening et al., 2012b)], and upregulating SERCA
expression [progesterone (Odening et al., 2012a; Odening et al.,
2012b; Moshal et al., 2014)], thereby exerting a protective, “anti-
arrhythmic” effect against drug-induced proarrhythmia (Odening
et al., 2012a; Odening et al., 2012b). These observations have
consequences for proarrhythmia research, as female animal
models (or animal models with altered hormonal state) might be
particularly sensitive in detecting potential ion channel-blocking
properties of drug candidates.
In this review, we first give an overview about currently
employed proarrhythmia markers, the importance of the choice
of species for proarrhythmia research, and the advantages and
disadvantages of currently used in vivo proarrhythmia models,
followed by a detailed description of novel transgenic LQTS
rabbit models. Finally, we provide a brief outlook on possible
future directions and novel models in the field.
Proarrhythmia ECG Markers for Temporal
Instability of Repolarization (Used in
In Vivo and In Vitro Models)
Based on the clinical observations that TdP mostly occurred in
the setting of prolongation of ventricular repolarization/QT
prolongation (Haverkamp et al., 2000; Redfern et al., 2003),
preclinical and clinical safety tests have for a long time focused
on QT prolongation as a surrogate marker for TdP risk (Food
and Drug Administration, 2005b). However, it has been known
for some time that prolongation of repolarization does not
always equally increase pro-arrhythmic risk since numerousFrontiers in Pharmacology | www.frontiersin.org 3drugs that block IKr/HERG and prolong QT rarely cause TdP—
while others causing less pronounced QT prolongation carry a
significant pro-arrhythmic risk (Zhang et al., 1999; Yang et al.,
2001; Roden, 2004; Thomsen et al., 2004; Shah and Hondeghem,
2005). Indeed, the extent of QT prolongation did not predict
serious ventricular arrhythmias and/or SCD in different rabbit
and dog experimental models (Amos et al., 2001; Thomsen et al.,
2004; Shah and Hondeghem, 2005; Lengyel et al., 2007a;
Jacobson et al., 2011) or in patients with (Strasberg et al., 1983;
Yi et al., 1998; Maron et al., 2001; Hinterseer et al., 2009;
Hinterseer et al., 2010) or without (Eisenberg et al., 1995;
Kusano et al., 2001; Paltoo et al., 2001) congenital/structural
heart disease. Thus, these safety tests can yield either false
positive results, halting the development of a promising new
drug (Roden, 2004; Hondeghem et al., 2007) or false negative
results, causing harm to patients with increased susceptibility to
arrhythmia. Therefore, there is an unmet need for (i) improved
identification of patients at elevated risk for drug-induced
arrhythmia (Kaab et al., 2003) and (ii) novel ECG markers
with better predictive value for pro-arrhythmic drug
adverse effects.
A number of different electrophysiological parameters have
been investigated as non-invasive prognostic markers for TdP
and SCD risk evaluation both in animal experiments and in the
clinical setting. These novel markers mostly derive from the
original work by Hondeghem et al., suggesting the assessment of
AP triangulation, instability, and dispersion (Hondeghem et al.,
2001). These markers were later supplemented by evaluation of
disturbances in cardiac wavelength (Hondeghem et al., 2007;
Hondeghem, 2016). The importance of an increased spatial
(transmural, apico-basal, or inter-ventricular) dispersion of
repolarization in reentry-based arrhythmia formation was
further supported by other studies (Antzelevitch, 2008;
Barbhaiya et al., 2013; Guerard et al., 2014). Therefore, Tpeak-
end—the length from the beginning of the T wave (Tp) to the end
(Te) on ECG—that reflect the transmural dispersion of
repolarization was suggested to use as an indicator of
arrhythmic risk, although, no clear consensus about the value
of this parameter has been reached so far (Antzelevitch, 2008;
Barbhaiya et al., 2013; Meijborg et al., 2014). Of note, dispersion
of repolarization was recently identified (experimentally and by
computational modeling) as cause for triggered activity/EAD
formation, further enhancing the need to assess dynamic
dispersion of repolarization noninvasively (Liu et al., 2018).
The temporal instability of cardiac repolarization can be
described by different variables characterizing the small beat-
to-beat fluctuations in the QT interval as QT variability [for a
recent review see (Baumert et al., 2016)]. Beat-to-beat variability
of repolarization can be quantified by calculating the short-term
variability of the QT (STVQT) (Thomsen et al., 2004). First in the
chronic AV-block dog model, then in other animal experimental
proarrhythmia models (Thomsen et al., 2004; Lengyel et al.,
2007a; Jacobson et al., 2011) and in clinical settings (Hinterseer
et al., 2008; Hinterseer et al., 2009; Hinterseer et al., 2010;
Oosterhoff et al., 2010), it has been repeatedly shown that
STVQT has a higher predictive value for proarrhythmia riskJune 2020 | Volume 11 | Article 853
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STVQT has been used in several studies to confirm the safety of
different drugs (Oros et al., 2006; Antoons et al., 2010;
Varkevisser et al., 2012), to characterize pro-arrhythmic drug
effects (Thomsen et al., 2004; Thomsen et al., 2006b; Kristof et al.,
2012), and to assess temporal repolarization instability in
patients with co-morbidities associated with repolarization
disturbances (Orosz et al., 2015a; Orosz et al., 2015b; Orosz
et al., 2017).
Based on the above, it is justified and required to assess and
validate measures of temporal QT variability in animal
experimental models of proarrhythmia.CURRENT IN VIVO MODELS FOR PRE-
CLINICAL PROARRHYTHMIA SAFETY
SCREENING AND THEIR LIMITATIONS
Choice of Models: Species Differences in
Repolarizing Currents
Cardiac electro-mechanical function shows large inter-species
variability. These species differences are especially striking in
regard to cardiac repolarization that is governed by tightly
regulated activities of various inward and outward ion currents.
Small rodents like mice or rats are commonly used animals
for studying ischemia-induced arrhythmias (which are often
linked to conduction properties), since cardiac conductionFrontiers in Pharmacology | www.frontiersin.org 4properties in these animals are governed by Na+ currents, Ca2+
currents, and connexin function that are very similar to those in
human (Derangeon et al., 2012; Kaese and Verheule, 2012).
Furthermore, they have the advantage of low cost, short life-
cycle, and their genetic manipulation is much easier than that in
larger animals (see Genetically Modified Mouse Models With
Reduced Repolarization Reserve). On the other hand; however,
they have limited value in studying (prolonged) repolarization-
related arrhythmogenesis: in mice and rats the fast and
slow transient outward (Ito), and the delayed rectifier (IK,slow1
and IK,slow2) (Xu et al., 1999; Brunner et al., 2001; Liu et al., 2008)
voltage-gated potassium currents play a major role in
repolarization—while in dogs, rabbits, and humans the rapid
and slow delayed rectifier potassium currents (IKr and IKs) are the
major determinants of cardiac repolarization (Varro et al., 1993;
Nerbonne, 2000; Nerbonne and Kass, 2005; Grandy et al., 2007;
Saito et al., 2009; Yang et al., 2014). The exact role of IKr and IKs
in small rodents is still not well known and controversial
(Nerbonne and Kass, 2005; Grandy et al., 2007; Saito et al.,
2009; Yang et al., 2014). As a result, the shape of their AP is
different compared to larger animals and humans (triangular
shape vs. rectangular AP with prominent plateau phase)
(Nerbonne and Kass, 2005; Grandy et al., 2007; Saito et al.,
2009; Yang et al., 2014), as well as their pharmacological
responses to proarrhythmic potassium channel blocking drugs
(Figures 1A, B).
Acute IKr-blocker administration, for example, prolongs
repolarization in dogs, rabbits, and humans but not in mice orA
B C
FIGURE 1 | Species differences in repolarizing ion currents. (A) Representative action potential (AP) recordings [modified from (Rudy et al., 2008; Blenck et al.,
2016)] and (B) schematic illustration of the main repolarizing ion currents in mouse, rabbit, dog, and human cardiomyocytes [modified from (Nerbonne et al., 2001)].
Panel (C) shows species differences in IKs, IKr, and IK1 in rabbit, dog, and human.June 2020 | Volume 11 | Article 853
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et al., 2014). Chronic administration of the IKr-blocker dofetilide
that prolongs repolarization in larger animals and human subjects
by blocking HERG channels on the other hand, lengthen
repolarization in mice—at least partly—by increasing INa,L (via
phosphoinositide 3-kinase pathway) (Yang et al., 2014). Based on
the above, mice and rats have serious limitations in drug-induced
proarrhythmia research with little translational potential.
In contrast, the function and gating kinetics of various cardiac
potassium channels are very similar in dogs, rabbits, and humans
with IKr and IKs as main repolarizing ion currents in all three
species (Varro et al., 1993; Nerbonne, 2000; Nerbonne and Kass,
2005; Jost et al., 2013), with slight inter-species differences: In
humans and dogs—just as in most mammals—Ito is formed of
two distinct subtypes named as Ito,fast and Ito,slow—with fast and
slow recovery from inactivation, determined by Kv3.4 and Kv1.4,
respectively (Patel and Campbell, 2005) as opposed to rabbits,
where Ito,slow is the primary transient Kv current in the left
ventricle (Fedida and Giles, 1991), while in the right ventricle Ito,
fast and its role in LQT1 related arrhythmogenesis has recently
been confirmed (Choi et al., 2018). The repolarization capacity of
rabbits and dogs is more robust than that in humans due to
higher IK1, IKr, and IKs current densities (Jost et al., 2013; Husti
et al., 2015) (Figure 1C).
In summary, the rabbit has a prominent role in arrhythmia
research, since: (i) the shape of AP (Varro et al., 1993) and the
function and gating kinetics of the underlying cardiac ion
channels/currents (Nerbonne, 2000), (ii) the myocardial
mechanical function (Jung et al., 2012), (iii) the relative
effective heart size relating cardiac mass to the frequency of VF
(Panfilov, 2006), and (iv) their responses to pharmacological
interventions (Harken et al., 1981) show very close resemblance
to human cardiac physiology. Based on the above-described
species differences in various ion currents, the rabbit could
have advantages over dog models when testing the
proarrhythmic potential of drugs with IKr, IKs, or IK1-blocking
properties since they show very good similarity to human
physiology in these currents and are cheaper, easier to handle,
and to breed than dogs and can be modified genetically. Dogs or
guinea pigs, on the other hand, may be better suited to use for
studying arrhythmogenesis in which Ito-inhibition plays an
important role.
In Vivo Proarrhythmia Models With
Reduced Repolarization Reserve
Both drug-induced and genetically modified animal models with
impaired repolarization reserve have been generated in various
species (such as dogs, mice, and rabbits) and utilized to
investigate drug-induced proarrhythmia and its underlying
mechanisms [reviewed in (Salama and London, 2007; Lang
et al., 2016)]. In addition, animal models with cardiac diseases
—e.g. chronic heart failure, hypertrophic cardiomyopathy,
diabetes mellitus etc.—leading to electrical remodeling-
associated alterations of repolarization reserve can be used for
proarrhythmia research. These models have the advantage thatFrontiers in Pharmacology | www.frontiersin.org 5they mimic some of the diseases that also predispose human
patients to drug-induced arrhythmias.
One main shortcoming of drug-induced animal models, however,
is the fact that drugs have to be administered continuously to sustain
the drug-induced reduction of repolarization reserve, thus impeding
detailed investigation of (long-term) proarrhythmia in free-moving,
non-anesthetized animals.
One main short-coming of genetically modified mouse
models—the only genetic models with reduced repolarization
reserve available until 2008—are the pronounced species
differences in cardiac electrophysiology with different ion
currents conveying cardiac repolarization in human and
murine cardiomyocytes (Varro et al., 1993; Nerbonne, 2000;
Nerbonne and Kass, 2005; Jost et al., 2013) as highlighted in the
subchapter above.
High cost and need for special technical expertise for example
are considered as main shortcomings for the generation of
disease-related animal models with cardiac electrical remodeling.
Drug-Induced Animal Models With Reduced
Repolarization Reserve
One frequently used drug-induced model is the methoxamine-
sensitized rabbit model: anesthetized rabbits are sensitized with
the selective a-adrenoceptor-agonist methoxamine, which
makes them particularly prone to develop drug-induced
ventricular tachycardia when exposed to HERG/IKr-blocking
drugs (Carlsson, 2008; Carlsson et al., 2009). The choice of the
anesthetic regimen, however, strongly influences the extent of
proarrhythmia development in this model—as the different
anesthetics all have different intrinsic cardiac ion channel-
blocking properties (Carlsson, 2008; Inaba et al., 2011),
indicating the importance of the degree of ion channel
blockade in these “mixed” drug-induced models. Pro- and
anti-arrhythmic properties of various different drugs have been
tested and classified as having a low, intermediate, or high pro-
arrhythmic potential for drug-induced TdP using this model
(Diness et al., 2008; Carlsson et al., 2009; Jacobson et al., 2011;
Mow et al., 2015; Varkevisser et al., 2015). However, as the model
depends on a-adrenoceptor sensitization, the full extent of pro-
arrhythmic potential of drugs that concomitantly block IKr and
a-adrenoceptors (such as quinidine, cisapride, quinolone) may
not be fully appreciated by this model (Carlsson, 2008; Mow
et al., 2015).
Other frequently employed drug-induced rabbit models are
based on the ex vivo blockade of HERG/IKr by E-4031 (Choi
et al., 2002; Maruyama et al., 2011; Parikh et al., 2012; Lau et al.,
2015) or by dofetilide (Farkas et al., 2006; Dhein et al., 2008;
Orosz et al., 2014), thus generating a drug-induced rabbit model
representing LQT2 characteristics. Similar to the genetic
reduction of IKr in congenital LQT2, the drug-blockade of IKr
by E-4031 or dofetilide leads to a high propensity for arrhythmia
development in ex vivo Langendorff-perfused rabbit hearts—
particularly when perfused with low K+ and Mg2+ solutions
(Maruyama et al., 2011; Milberg et al., 2011). Similarly, QTc
prolongation and arrhythmia susceptibility is particularly highJune 2020 | Volume 11 | Article 853
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blockade by HMR-1556 (Lengyel et al., 2007a) (Figure 2A).
Genetically Modified Mouse Models With Reduced
Repolarization Reserve
Despite apparent differences between human and mouse
electrophysiology—e.g., different ion currents conveying cardiac
repolarization in human and murine cardiomyocytes, a different
shape of the AP, and a magnitude-faster heart rate in mice
[reviewed in (Nerbonne, 2000); (Salama and London, 2007);
(Baczko et al., 2016)], the first transgenic and knock-out animal
models of LQTS were mouse models (London et al., 1998). The
reason for this was that genetic manipulation has for a long time
nearly exclusively been feasible in mice and not in other larger
mammals such as rabbits. Transgenic models based onmutations in
human potassium channel genes or knock-out/knock-in models of
mouse potassium channel genes could only partially mimic the
characteristics of human patients with impaired repolarization
reserve [reviewed in detail in (Nerbonne et al., 2001); (LangFrontiers in Pharmacology | www.frontiersin.org 6et al., 2016); (Ziupa et al., 2019)], while genetically modified
mouse models with mutations in the sodium channel gene
(SCN5A; LQT3) more closely mimic the human long QT disease
phenotype with AP duration (APD) and QT prolongation as well as
spontaneous life-threatening ventricular arrhythmia (Nuyens et al.,
2001; Fabritz et al., 2003), since SCN5A drives the majority of
depolarizing Na+ currents in both human and murine
cardiomyocytes (Derangeon et al., 2012).
None of these mouse models, however, have been systematically
used for proarrhythmia research—mainly due to the fact that IKr
current (themost frequent target for drugs inducing proarrhythmia)
plays no major role in cardiac repolarization in mice.
Animal Models With Structural/Electrical Remodeling
and Reduced Repolarization Reserve
Several experimental animal models of different species exist that are
characterized by impaired repolarization reserve associated with
cardiac structural and/or electrical remodeling. The most
thoroughly characterized of these is the canine cardiac volumeA
B
C
FIGURE 2 | Pro-arrhythmia detection with acquired LQT rabbit and chronic AV-block dog models. (A) Left panel: The QTc interval was significantly prolonged by
the IKr blocker dofetilide and was further prolonged by the combination of dofetilide and the IKr blocker HMR1556 given in any order, while IKs block alone did not
prolong the QTc in anesthetized rabbits. Right panel: IKr block caused TdP in some of the animals, IKs block alone did not induce TdP in anesthetized rabbits.
Importantly, combined acute pharmacological block of IKs and IKr, given in any order, caused a significant increase in TdP incidence. #p < 0.05 vs. baseline control in
the same group; *p < 0.05 vs. dofetilide. N=7-11 animals/group. CTRL: Control, DOF: Dofetilide, HMR: HMR-1556. Modified from (Lengyel et al., 2007a). (B) In right
ventricular cardiomyocytes isolated from dogs with chronic AV-block and marked myocardial hypertrophy, IKs tail current density was reduced by approximately 55%
(n=9), while IKr tail current density was reduced by 45% (n=14) compared to those isolated from control animals. *p < 0.05 vs. control myocytes. Modified from
(Volders et al., 1999). (C) Standard bipolar ECG lead recordings illustrating a marked difference in the arrhythmogenic response to administration of the selective IKr
blocker D-sotalol in dogs with acute (left panel) and chronic AV-block (right panel). The pacing protocol involved a basic pacing cycle length (CL) of 1730 ms in acute
AV block, and 1800 ms spontaneous idioventricular CL in chronic AV-block. Arrhythmia provocation included a short/long/short sequence at 600 ms CL for 4 beats
followed by 2 paced beats with 1200 and 350 ms cycle lengths. No TdP was observed in acute AV-block dogs, while 60% of animals with chronic AV-block
exhibited TdP. Modified from (Vos et al., 1998).June 2020 | Volume 11 | Article 853
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1995). Three months following AV-node ablation, these dogs
exhibit severe bradycardia and eccentric, biventricular myocardial
hypertrophy without heart failure (Vos et al., 1998). Importantly,
the model is characterized by heterogeneous prolongation of APD
at baseline and further APD-prolongation and early
afterdepolarization (EAD) development upon administration of
IKr-blocker d-sotalol, indicating increased susceptibility to drug-
induced TdP (Vos et al., 1998) (Figure 2C). A significant
downregulation of potassium currents, including IKs—a key player
in ventricular repolarization reserve in mammals including humans
(Varro et al., 2000; Volders et al., 2003; Jost et al., 2005)—was
observed in both left and right ventricular cardiomyocytes isolated
from dogs with chronic AV block (Volders et al., 1999) (Figure 2B).
In addition, IKr density was reduced by 45% in right ventricular
myocytes, while left ventricular (LV) IKr density was unchanged
(Volders et al., 1999).
The ability of the model to detect drug-induced TdP was
validated (Takahara et al., 2006) with several drugs such as the
H1 antihistamine terfenadine (Monahan et al., 1990),
the antipsychotic drug sertindole (Thomsen et al., 2003), and
the D2 dopamine receptor antagonist sulpiride (Sugiyama et al.,
2002). Moreover, with this model, it was demonstrated for the
antibiotics moxifloxacin and azithromycin that QT prolongation
does not necessarily cause TdP (Thomsen et al., 2006a). An
important advantage of this model is an improved
proarrhythmia reproducibility within the same experimental
animal (Verduyn et al., 2001). There are, however, some
disadvantages that may prevent this model from becoming
widely used for proarrhythmia research: it is a relatively
expensive, time consuming (at least 3 months have to pass
before ventricular hypertrophy and increased susceptibility to
arrhythmia develops) and low throughput method that requires
special technical expertise for performing AV-node ablation
(Vos et al., 1998).
In diabetes, a moderate remodeling-associated QT
prolongation has been shown (Giunti et al., 2007), and
diabetes has been associated with increased risk of SCD (Gill
et al., 2009), indicating the patients' higher susceptibility to
proarrhythmia. Similarly, in rabbit and dog models of diabetes
mellitus, a mild prolongation of repolarization and a decreased
repolarization reserve due to downregulation of IKs and Ito
(reversible by insulin treatment) were observed (Lengyel et al.,
2007b; Lengyel et al., 2008). The authors are not aware, however,
of any published studies using experimental diabetes animal
models in species with repolarization relevant to human (i.e. not
mice or rats) for testing pro-arrhythmic effects of drugs in this
“patient” cohort.TRANSGENIC LQTS RABBIT MODELS
WITH IMPAIRED REPOLARIZATION
RESERVE (LQTS)
Since cardiac electrophysiological characteristics of the rabbit is
much closer to humans than that of mice or rats (Varro et al.,Frontiers in Pharmacology | www.frontiersin.org 71993; Nerbonne, 2000; Nerbonne and Kass, 2005; Jost et al.,
2013),—similar potassium currents (mainly IKr and IKs) convey
the cardiac repolarization in rabbits and humans—transgenic
LQTS rabbit models were generated as soon as it became
technically feasible (Bosze et al., 2016) to better mimic
pathophysiology of (human) LQTS patients with decreased
repolarization reserve, who are most vulnerable to the
development of drug-induced arrhythmias.
Generation of Transgenic LQTS
Rabbit Models
To generate transgenic LQTS rabbit models with impaired
repolarization reserve, the so-called “dominant-negative”
transgenic strategy, which describes the fact that the co-assembly
of mutated and normal channel subunits completely disrupts the
overall ion channel function, was utilized to decrease the expression
of functionally normal repolarizing potassium channel proteins. All
available transgenic LQTS rabbit models have been engineered by
beta-myosin heavy chain promoter-driven cardio-selective over-
expression of mutated human genes encoding for voltage-gated K+
channels such as KCNQ1/KvLQT1 (KvLQT1-Y315S, LQT1),
KCNH2/HERG (HERG-G628S, LQT2), or KCNE1/minK
(KCNE1-G52R) (Brunner et al., 2008; Major et al., 2016).
To generate the transgenic founder animals, the pronuclear
microinjection technique was used. Superovulation was induced
in wild-type (WT) rabbits using hormonal stimulation with FSH
and GnRH-analogues, and inseminated oocytes were
microinjected with transgenic mutant DNA-constructs and re-
implanted into foster mothers (Brunner et al., 2008; Major et al.,
2016). Mating of the resulting transgenic F0 founders with
female WT rabbits resulted in vertical transmission with 50%
transgenic and 50% WT offspring. To generate double-
transgenic LQT2–5 rabbits, LQT2 male and LQT5 female
rabbits were cross-bred (Hornyik et al., 2020).
Electrophysiological Characteristics and
Arrhythmogenic Mechanisms in the
Transgenic LQTS Models
In LQT1 or LQT2 rabbit cardiomyocytes the repolarizing
potassium currents IKs (LQT1) or IKr (LQT2), respectively, are
completely eliminated. This results in a prolongation of APD on
the cellular and whole heart levels and a prolongation of
ventricular refractoriness and QT interval duration in vivo
(Brunner et al., 2008; Odening et al., 2010). This prolongation
of APD/QT is particularly pronounced at slower heart rates,
leading to a steeper QT/RR ratio—particularly in LQT2 (Brunner
et al., 2008) (Figures 3A–C). Moreover, these models
demonstrate an increased temporal instability of QT duration
with an increased STVQT (Hornyik et al., 2020) and spontaneous
polymorphic VT in LQT2 [158] (Figure 3D).
In transgenic LQT5 rabbit cardiomyocytes, in contrast, the
biophysical properties of IKs and IKr are altered with accelerated
deactivation kinetics (Major et al., 2016)—but overall IKs and IKr
current densities are not reduced. Consequently, these rabbits
exhibit only a partial phenotype with no significant prolongation
of whole heart APD (Major et al., 2016; Hornyik et al., 2020), andJune 2020 | Volume 11 | Article 853
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changes in QT/RR ratio (Major et al., 2016; Hornyik et al., 2020)
(Figures 3A–C), but exhibit an increased short-term beat-to-
beat variability of the QT (Major et al., 2016). Due to their
reduced repolarization reserve, the phenotype can be augmented
by the IKr-blocking drug dofetilide, which further increased
short-term variability of QT and promoted drug-induced VT
(Major et al., 2016).
Studies in transgenic LQT1 and LQT2 rabbits highlight the
major role of an enhanced (spatial and temporal) dispersion of
repolarization in LQTS-related arrhythmogenesis: in LQT2
rabbit hearts, an increased spatial dispersion of APD was
observed throughout left and right ventricles (Brunner et al.,
2008; Odening et al., 2013) (Figure 4A). Dispersion of
repolarization can also occur in a dynamic spatio-temporal
fashion with pronounced beat-to-beat alternations and “out-of-
phase” heterogeneities between adjacent regions, the so-called
“discordant alternans”. In transgenic LQT2 rabbit hearts, this
discordant alternans developed at physiological heart rates and
preceded VT/VF formation (Ziv et al., 2009). VT/VF were easily
inducible with LV epicardial stimulation (Brunner et al., 2008),Frontiers in Pharmacology | www.frontiersin.org 8and, importantly, LQT2 rabbits even developed spontaneous
polymorphic VT and SCD (Brunner et al., 2008; Odening
et al., 2012b), thus representing the first transgenic animal
models mimicking the complete electrical phenotype of LQT2.
Transgenic LQT1 rabbits with a more homogeneously prolonged
APD without substantial dispersion of repolarization within the
LV at physiological/normal heart rates, in contrast, developed no
spontaneous VT or SCD (Brunner et al., 2008). When LQT1
hearts were further stressed, however, by continuous tachypacing
or AV-ablation to induce cardiac tachymyopathy (Lau et al.,
2015), or complete AV-block (Kim et al., 2015), respectively,
APD dispersion increased, spatially discordant alternans
developed and VT/VF was easily inducible or occurred
spontaneously. Transgenic LQT5 rabbits demonstrated an
increased apico-basal APD heterogeneity compared to healthy
WT hearts at baseline—despite their overall “normal” APD
(Hornyik et al., 2020).
In addition to increased temporal instability and regional
heterogeneity of repolarization that form the electrical
“substrate” that facilitates re-entry formation, an increased
sympathetic nervous system activity serves as “trigger” forA B C
D
FIGURE 3 | Baseline electrical characteristics of transgenic LQTS rabbits. (A) Upper panel: IV-curves of IKs steady (left)/tail (right) and IKr steady (left)/tail (right) in
cardiomyocytes isolated from wild-type (WT), LQT1, and LQT2 rabbit hearts, indicating loss of IKs in LQT1 and loss of IKr in LQT2 [modified from (Brunner et al.,
2008)]. Lower panel: IV-curves of IKs in absence and presence of 5 µM forskolin in WT or transgenic LQT5 rabbit ventricular myocytes. Bar diagrams illustrate a
reduced deactivation time constant in transgenic LQT5 ventricular myocytes [modified from (Major et al., 2016)]. (B) Representative ECG tracings indicating
differences in QT interval in WT, LQT1, LQT2, and LQT5 rabbits [ECG from WT, LQT1 and LQT2 modified from (Brunner et al., 2008)]. (C) QT/RR relationship
assessed with telemetric ECG in free moving rabbits: WT, LQT1, and LQT2 in upper panel [modified from (Brunner et al., 2008)], in lower panel in WT and LQT5
[modified from (Hornyik et al., 2020)]. (D) ECG and blood pressure tracing of LQT2 rabbit with spontaneous ventricular torsade-de-pointes (TdP) tachycardia
[modified from (Brunner et al., 2008)]. *p < 0.05 vs. WT.June 2020 | Volume 11 | Article 853
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Brunner et al., 2008; Ziv et al., 2009). In LQT2 cardiomyocytes,
beta-adrenergic stimulation related EADs developed during
sudden sympathetic surge (Figure 4B), while continuous
perfusion with beta-agonist isoproterenol prevented EAD
formation (Brunner et al., 2008; Liu et al., 2012; Odening et al.,
2012b). In LQT1 cardiomyocytes, in contrast, continuous beta-
adrenergic stimulation facilitated the occurrence of EADs (Liu
et al., 2012). Different time courses in sympathetic activation of
cardiac ion currents may explain why different sympathetic
modes (sudden surge vs. continuous activation) are associated
with arrhythmia formation in different genotypes of LQTS: upon
sympathetic stimulation, beta-1 receptor mediated activation of
ICa,L—that may elicit EADs—is faster than the activation of IKs—
that shortens APD in LQT2 and acts as anti-arrhythmic
mechanism upon continuous adrenergic stimulation in LQT2.
In addition, different modes of arrhythmia initiation and
maintenance in different LQTS genotypes were identified.
While in LQT2, reentry formation played an important role
(Brunner et al., 2008), in LQT1 hearts, a novel mechanistic
concept of LQTS-related arrhythmogenesis was identified:Frontiers in Pharmacology | www.frontiersin.org 9arrhythmia was initiated by focal excitations arising
particularly from the RV and was maintained by multiple
shifting excitation foci and bi-excitability (Kim et al., 2015).
Similarly, as in the LQT5 rabbit models, the phenotype and
proarrhythmia could be augmented by ion channel blocking
drugs and endogenous factors (as highlighted in the
following subchapters).
Pro-Arrhythmic Effects of Endogenous
Factors (Hormones and Metabolites) in
Transgenic LQTS Rabbit Models With
Impaired Repolarization Reserve
Pronounced sex differences in arrhythmic risk have been identified
in patients with congenital and acquired, drug-induced LQTS with a
higher risk for cardiac arrhythmic events in women after puberty
than men (Lehmann et al., 1996; Locati et al., 1998; Benton et al.,
2000; Wolbrette, 2003; Gowda et al., 2004; Yang and Clancy, 2011).
Moreover, while the risk for long QT-related arrhythmia is reduced
during pregnancy (Seth et al., 2007), it is particularly high risk
during the postpartum (particularly in LQT2 patients) (Sauer et al.,
2007). In addition, more pronounced QT-prolongation andJune 2020 | Volume 11 | Article 85A
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FIGURE 4 | Mechanisms of arrhythmogenesis in transgenic LQT2 rabbits. (A) Upper panel (i): Bar graphs of action potential durations (APD) and dispersion of APD
(DAPD) in Langendorff-perfused hearts of WT, LQT1, and LQT2 rabbits indicate longer APD and increased APD dispersion in LQT2 hearts, *p < 0.05 [modified from
(Brunner et al., 2008)]. Lower panel (ii): optical mapping APD map (left; indicated are isochrones of APD, in ms) and activation maps (right) of initial beats of
ventricular tachycardia/fibrillation (VF) in an estradiol-treated LQT2 heart indicate reentry formation (indicated by red arrows) in line with the regional APD
heterogeneities [modified from (Odening et al., 2012b)]. (B) Representative trace of Ca2+ oscillations and early afterdepolariaztion (EAD) in estradiol-treated LQT2
rabbit heart after AV-node ablation and bolus application of isoproterenol (140 nM). Black line indicates changes in voltage fluorescence signal (Vm); red line indicates
changes in Ca2+ signal [modified from (Odening et al., 2012b)].3
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menstrual cycle (Rodriguez et al., 2001), strongly suggesting that
changing sex hormone levels may affect LQTS-related
arrhythmogenesis. This has consequences for proarrhythmia
research, as female animal models might be particularly sensitive
in detecting potential ion channel-blocking properties of
drug candidates.
In transgenic LQT2 rabbits, spontaneous ventricular arrhythmia
and SCD also often occurred during postpartum (Brunner et al.,
2008; Odening et al., 2012b), suggesting the existence of similar
arrhythmia-triggering mechanisms as in human LQTS patients. In
these models, estradiol exerted a pro-arrhythmic effect with an
increased incidence of lethal polymorphic TdP due to changes in
APD dispersion and increased EAD formation upon pro-
arrhythmic sympathetic stimuli, while progesterone had an anti-
arrhythmic, protective effect that was based on a shortening of
cardiac refractoriness, a reduced formation of EAD, and stabilizing
Ca2+ effects (decreased ICa,L density, increased SERCA expression)
(Odening et al., 2012b). These studies suggest that progesterone-
based therapies may be considered as novel anti-arrhythmicFrontiers in Pharmacology | www.frontiersin.org 10approaches in female LQTS patients; and might be considered as
therapeutic add-on in cases of severe drug-induced long-QT related
proarrhythmia (Odening et al., 2012b). As estradiol-treated hearts
are particularly sensitive to proarrhythmia, their use in
proarrhythmia research, in contrast, might increase sensitivity to
identify candidates with a pro-arrhythmic potential.
Similarly, the postpartum-related hormones oxytocin and
prolactin decreased IKs current densities, thereby prolonging
the APD/QT further and predisposing the heart to arrhythmias
(Odening et al., 2019).
Hormones as well as other endogenous factors such as
certain metabolites may impact on repolarization reserve: it
has been demonstrated that (genetic) metabolic disturbances
such as propionic acidemia can also cause acquired LQTS
(Kakavand et al., 2006; Baumgartner et al., 2007; Jameson and
Walter, 2008), thus rendering patients at increased risk
for additional drug-induced proarrhythmia. Using rabbit
models of LQTS, we could identify a propionic acid-induced
reduction of IKs current densities as underlying mechanism
(Bodi et al., 2016).A
B
FIGURE 5 | Pro-arrhythmic drug-effects in transgenic LQTS rabbit models: changes in pro-arrhythmia markers. (A) Changes in in vivo pro-arrhythmia markers. (i.)
Bar graphs show changes in QTc, STVQT, and Tpeak-Tend in anaesthetized animals after i.m. injection of IKr, IK1, and IKs-blockers dofetilide, BaCl2, HMR-1556,
respectively in WT, LQT2, LQT5, and LQT2–5 rabbits [modified from (Hornyik et al., 2020)]. *p < 0.05 inter-genotype comparison, #p < 0.05 vs. baseline, T trend
p < 0.1 vs. baseline. (ii.) IK1-blocker midazolam-induced change in heart-rate corrected QT-index in free-moving male (solid bars) and female (hatched bars) WT,
LQT1, and LQT2 rabbits is also shown. The dashed line represents the mean QT indexes in free-moving rabbits obtained with the genotype-specific correction
formula (=100%) [modified from (Odening et al., 2008)]. *p < 0.05 vs. free-moving rabbits of the same genotype. (iii.) Bar graphs indicate IKr-blocker dofetilide-
induced increase in STVQT in WT and LQT5 animals [modified from (Major et al., 2016)]. Bsl, baseline; Dof, dofetilide.*p < 0.05 inter-genotype comparison,
#p < 0.05
vs. baseline. (B) Changes in ex vivo pro-arrhythmia markers. Bar graphs of changes in action potential duration (DAPD75), action potential duration/stimulation cycle
length ratio (DAPD/CL ratio and action potential triangulation (DAPD90-30) after 10 min perfusion with IKr, IK1 and IKs-blockers dofetilide, BaCl2 and HMR-1556,
respectively in WT, LQT2, LQT5, and LQT2–5 rabbits. *p < 0.05 inter-genotype comparison, #p < 0.05 vs. baseline [modified from (Hornyik et al., 2020)].June 2020 | Volume 11 | Article 853
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for Better Detection of Drug-Induced
Ventricular Arrhythmias
Drug-induced proarrhythmia is based on regionally
heterogeneous prolongation of cardiac repolarization caused by
various groups of drugs blocking multiple ion channels. As it
most-often occurs in patients with reduced repolarization reserve
(see above), the use of various transgenic LQTS rabbit models
(Brunner et al., 2008; Major et al., 2016) with increased
sensitivities to potassium channel blocking effects and different
degrees of impairment in their cardiac repolarization reserve, is
expected to provide more reliable, and more thorough detection
of (multi-channel-based) drug-induced ventricular arrhythmias.
Indeed, it has been shown that LQT1 rabbits lacking IKs and
LQT5 rabbits with impaired IKs function were particularly
sensitive in identifying IKr-blocking properties of drugs; while
transgenic LQT2 rabbits lacking IKr demonstrated a particularly
high sensitivity to IKs- or IK1-blocking drugs (Volders et al.,
2003; Jost et al., 2005; Odening et al., 2010; Odening et al.,
2013; Hornyik et al., 2020) as further outlined in the
following subchapters.
Investigation of Drug-Induced Changes
in Proarrhythmia Markers in Transgenic
LQTS Rabbit Models
Drug-induced arrhythmia is a relatively rare event, and
arrhythmia development as “hard endpoint” cannot be directly
studied—especially during “first-in-human” clinical trials.
Therefore, model systems with increased susceptibility for
proarrhythmia are employed for safety testing and changes in
various proarrhythmia markers are monitored to assess the pro-
arrhythmic potential of the investigated/applied drug.
Several biomarkers have been suggested to use for
proarrhythmia screening that reflect changes in various aspects
of repolarization such as: (i) duration (QTc, APD), (ii) spatial
(Tpeak-end, APD dispersion), and (iii) temporal dispersion
(STVQT, QT/RR steepness, APD restitution) of repolarization
(for more details, see previous sections). These were also
employed in the different transgenic LQTS rabbit models.
Transgenic LQT2 rabbits demonstrated a high sensitivity to
IKs- or IK1-blocking anesthetic agents such as isoflurane (IKs) or
the anxiolytic sedative midazolam (IK1) as demonstrated by a
particularly pronounced prolongation of QT and heart-rate
corrected QT index as compared to healthy rabbits (Odening
et al., 2008) (Figure 5A). In addition, a pronounced increase in in
vivo ECG proarrhythmia markers (QT, STVQT, and Tpeak-end)
and ex vivo monophasic AP related proarrhythmia markers
(APD, AP triangulation and APD restitution steepness)
indicated higher susceptibility also to other IK1 and IKs
blocking compounds (BaCl2 and HMR-1556) in transgenic
LQT2 and double-transgenic LQT2–5 rabbits (Hornyik et al.,
2020) (Figures 5A, B).
LQT1 and LQT5 models; on the other hand, were especially
sensitive to IKr blockade (dofetilide, E4031, and erythromycin),
as demonstrated in vivo by a pronounced increase in QTc,
STVQT, and Tpeak-end and ex vivo by a prolongation of APDFrontiers in Pharmacology | www.frontiersin.org 11and (in LQT1) APD dispersion (Odening et al., 2010; Ziupa et al.,
2014; Major et al., 2016).
Investigation of Ex Vivo Susceptibility to Arrhythmia
in Isolated Transgenic LQTS Rabbit Hearts
The direct assessment of ex vivo arrhythmia development in
isolated Langendorff-perfused transgenic LQTS rabbit hearts
were first performed by Hornyik et al., using different
provocation factors—such as bradycardia, low [K+]o, and/or
application of K+-channel blockers—that are also crucial in
drug-induced proarrhythmia formation in the clinical setting
(Hornyik et al., 2020). It was shown that the application of IK1-
blocker BaCl2 alone already significantly increased the incidence
and duration of ventricular extra beats in LQT2 and LQT2–5
hearts (Figure 6A). When the pre-existing temporal, beat-to-
beat-QT-instability, and the prolonged, regionally heterogeneous
repolarization were even further aggravated by lowering the
[K+]o, the sensitivity for re-entry formation was increased,
leading to significantly longer duration and higher incidence of
more malignant type of ventricular arrhythmias (VT and VF) in
LQT2 and LQT2–5 but not in healthy WT hearts (Figure 6A). In
LQT5 hearts with less pronounced reduction of repolarization
reserve, only less severe types of ventricular arrhythmias
(bigeminy) were detected. These observations of a higher
sensitivity of transgenic LQTS hearts to potassium channel
blocking drugs than normal WT hearts suggests that the use of
different transgenic LQTS rabbits might help in more reliably
detect drug-induced proarrhythmia.
Investigation of In Vivo Susceptibility to Arrhythmia
of Transgenic LQTS Rabbits
High in vivo susceptibility to arrhythmia of transgenic LQTS
rabbit models were demonstrated as early as the first
characterizations of the models were performed.
In transgenic LQT2 rabbit models, exhibiting regionally
heterogeneous prolongation of repolarization, VT and VF
easily occurred spontaneously resulting in high SCD rates
(Brunner et al., 2008). In addition, a further reduction of
repolarization reserve by the IKs-blocker isoflurane or by the
Ito-/IKs-blocker propofol led to increased proarrhythmia with a
variety of arrhythmic events such as AV 2:1 blocks, T-wave
alternans, PVCs, bigeminy, and lethal TdP occurring even during
short episodes of anesthesia (Odening et al., 2008) (Figure 6B).
Transgenic LQT1 rabbits with normal/physiological heart
rates and/or without organic heart diseases exhibited relatively
homogenous prolongation of repolarization in the LV without
substantial increase in APD dispersion; therefore, no
spontaneous arrhythmias and SCD were detected (Brunner
et al., 2008). When the repolarization reserve of LQT1 rabbits
were further challenged by continuous tachypacing or AV-
ablation to induce cardiac tachymyopathy (Lau et al., 2015), or
complete AV-block (Kim et al., 2015), respectively, however,
significant APD dispersion and discordant alternans developed
and VT/VF was easily inducible and even occurred
spontaneously (Lau et al., 2015). The model also demonstrated
the development of pseudo-AV blocks and drug-induced TdPJune 2020 | Volume 11 | Article 853
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Ziupa et al., 2014; Major et al., 2016; Ziupa et al., 2019)
(Figure 6B).
The recently generated LQT5 model with slight reduction in
IKs function similarly demonstrated more pronounced IKr-
blocker dofetilide induced TdP formation in vivo than healthy
WT rabbits (Major et al., 2016) (Figure 6B).
Limitations of the Currently Available
Models and Outlook
As the “dominant-negative” transgenic strategy was used to
generate the LQTS rabbits, instead of a rabbit gene “knock-
out”/human transgene “knock in” approach; these models are
genetically distinct from LQTS patients. Newly emerging genetic
engineering techniques such as CRISPR-cas [as described in
details in (Bosze et al., 2016)] may help to develop novel—also
genetically closer—animal models for these human diseases. As
currently available models demonstrate a LQTS phenotype,
however, with different degrees of reduction in repolarization
reserve and increased susceptibility to arrhythmia both
spontaneously and particularly upon drug-induced ion channel
blockade, they could still represent valuable models forFrontiers in Pharmacology | www.frontiersin.org 12proarrhythmia safety testing in the context of reduced
repolarization reserve.
Furthermore, compensatory electro-mechanical adaptation of
cardiomyocytes in response to the altered function (“cardiac
remodeling”) can also show species differences that could
influence their arrhythmia sensitivity. In transgenic LQTS
mice, for example, the observed compensatory upregulation of
non-affected potassium currents limit their use in identifying
repolarizing prolonging—potentially pro-arrhythmic—agents, as
opposed to transgenic LQTS rabbits, in which parallel decrease in
reciprocal repolarizing current(s) was seen (Brunner et al., 2008)
that even further increased the sensitivity of these models to
detect drug-induced proarrhythmia. Currently, very little is
known about the nature and extent of these compensatory
remodeling processes in human diseases with impaired cardiac
repolarization reserve; therefore, it is not known, which animal
model mimics most accurately human pathophysiology from
this aspect.
In spite of similarities in cardiac ion channels in rabbits and
humans, cardiac repolarization is still conveyed through ion
channels with slightly different biophysiological characteristics
in each species; therefore, caution has to be applied whenA
B
FIGURE 6 | Pro-arrhythmic drug-effects in transgenic LQTS rabbit models: arrhythmia development. (A) Ex vivo arrhythmia development. Graphs indicating the
duration (% of perfusion time) of arrhythmias provoked by perfusing the hearts with low [K+]o (2 mM) KH, or with combined low [K
+]o (2 mM) KH and IK1-blocker
BaCl2 (10 µM) in WT, LQT5, LQT2 and LQT2–5 animals. Inlets show representative ECG recordings of ventricular escape rhythm (VER), ventricular extra beats (VEB),
bigeminy, ventricular tachycardia (VT) and ventricular fibrillation (VF) [modified from (Hornyik et al., 2020)]. *p < 0.05 inter-genotype comparison. (B) In vivo arrhythmia
development. (i.) Bar graphs of dofetilide-induced incidence (in %) and log duration of torsade de pointes (TdP) tachycardia in WT and LQT5 rabbits [modified from
(Major et al., 2016)]. *p < 0.05 inter-genotype comparison. (ii.) Episode of polymorphic TdP tachycardia in female LQT2 rabbit during propofol anesthesia (acquired
with telemetric ECG) [modified from (Odening et al., 2008)]. (iii.) Episode of dofetilide-induced pVT in male LQT1 rabbit during episode of alternating AV 2:1/3:1 block
[modified from (Odening et al., 2010)].June 2020 | Volume 11 | Article 853
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models into humans.
Current animal models focus on the detection of repolarization
prolonging pro-arrhythmic effects. Drug-induced proarrhythmia
may, however, also occur upon pathologically pronounced
acceleration/shortening of cardiac repolarization (Malik, 2016).
Here, novel models such as the transgenic short QT syndrome
rabbit model (Odening et al., 2019), may be particularly useful for
the detection of these pro-arrhythmic drug properties.
Further improvement of current in silico proarrhythmia
screening capabilities by integrating experimental in vivo, whole
heart, cellular, and ion channel data into computational models are
highly warranted (Sager et al., 2014; Colatsky et al., 2016), and could
potentially lead to better assessment of mutation-specific aspects of
a wide range of cardiac channelopathies, since currently available
animal models mimicking cardiac channelopathies are very limited.
Importantly, the future use of patient-specific and/or disease-
specific human induced pluripotent stem cell derived
cardiomyocytes (iPSC-CM) has the potential to become a relevant
additional patient/disease-specific in vitro safety screening platformFrontiers in Pharmacology | www.frontiersin.org 13to test the pro-arrhythmic potential of novel drug candidates
(Mehta et al., 2013; Sager et al., 2014; Colatsky et al., 2016).AUTHOR CONTRIBUTIONS
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